CureMetrix

What CureMetrix does

CureMetrix, Inc. is a San Diego-based medical technology company founded in 2014 that develops FDA-cleared AI-powered software as a medical device (SaMD) for mammography analysis. The company's product suite centers on detecting and localizing Breast Arterial Calcifications (BAC) on routine screening mammograms — converting standard breast cancer screening exams into dual-purpose tools that simultaneously flag cardiovascular risk without additional radiation or procedures. Its flagship product, cmAngio (510(k) K250754, cleared October 2023), is the first FDA-cleared AI solution for BAC detection and localization, achieving .98 AUC, 94% sensitivity, and 96% specificity across both FFDM and DBT mammograms. The company also markets cmTriage (FDA-cleared 2019, K183285) for mammography workflow optimization and is developing cmAssist (cancer detection with region-of-interest highlighting) and cmDensity (automated BI-RADS breast density classification).

CureMetrix generates revenue through subscription-based SaaS licensing of its FDA-cleared SaMD products to healthcare providers and imaging centers, deployed via direct enterprise sales supported by a National Account Team that provides personalized demos, ground-truth studies, IRB protocol support, and data-sharing initiatives. Products are distributed through direct enterprise sales as well as through integration partnerships with Microsoft Precision Imaging Network, CARPL.ai, Ferrum Health, Covera Health, Therapixel, and other radiology AI platforms, with deployment at over 400 clinical sites including enterprise customers such as Northwell Health and Rezolut Imaging.

The company holds a multi-jurisdictional regulatory footprint spanning FDA clearance in the US, ANVISA registration in Brazil, MDSAP certification, ISO 13485, and ISO 27001, and has been the subject of a $307 million acquisition announcement by Stryker to bolster its AI-enabled imaging capabilities for robotic-assisted care pathways.

Name

CureMetrix

Legal name

CureMetrix, Inc.

Website

https://curemetrix.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

CureMetrix develops FDA-cleared AI software for mammography analysis, detecting breast arterial calcifications and cardiovascular risk on routine screening mammograms for healthcare providers and imaging centers, deployed at 400+ clinical sites.

Ownership category

akta.pro rank

Product category

Medical Imaging AI Software

NAICS

Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG)

akta.pro secondary industries

Breast Imaging Centers (Mammography/Tomosynthesis) (HLAFAKAD), SaMD – Digital Biomarkers & Algorithmic Endpoints (HLACANAF)

Keywords

• AI mammography software
• Medical imaging AI
• Breast cancer detection
• Cardiovascular risk screening
• FDA-cleared SaMD

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

1. FDA-cleared SaMD Software Licensing: SaaS-based deployment of AI-powered medical device software within licensed healthcare provider and imaging facility environments. Products require separate agreements for access and use.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

CureMetrix develops and sells FDA-cleared AI-powered Software as a Medical Device (SaMD) for mammography analysis. Its flagship product cmAngio detects and localizes Breast Arterial Calcifications (BAC) on routine screening mammograms, transforming standard breast cancer screening into a dual-purpose exam that simultaneously surfaces cardiovascular risk. The portfolio includes cmAngio, cmTriage (workflow optimization), cmAssist (cancer detection scoring), and cmDensity (breast density analysis).

Product overview

CureMetrix develops a suite of FDA-cleared AI-powered SaMD (Software as a Medical Device) products for mammography analysis. The portfolio consists of four products: cmAngio (FDA-cleared October 2023) for breast arterial calcification detection and localization; cmTriage (FDA-cleared) for mammography workflow optimization; cmAssist (in development) for cancer detection scoring with AI-powered region-of-interest highlighting; and cmDensity (in development) for automated breast density classification. cmAngio is the lead product and first FDA-cleared AI solution for BAC detection, achieving .98 AUC performance. The products are designed for deployment within licensed healthcare provider and imaging facility environments, with PACS integration capabilities. Regulatory status includes FDA clearance in the US and ANVISA registration in Brazil, with global expansion in progress targeting Canada, Australia, EU, and other markets.

Differentiator

Problem solved

Functional benefit

Brands

• cmAngio: FDA-cleared AI-powered breast arterial calcification (BAC) detection and localization solution for mammography.
• cmTriage
• cmAssist
• cmDensity

Products and services

• cmAngio FDA-cleared AI-powered platform for quantitative Breast Arterial Calcification (BAC) detection and localization on routine screening mammograms. Analyzes both FFDM and DBT mammograms, generates a cmAngio Scorecard, and delivers results in minutes with .98 AUC accuracy. Deployed at 400+ clinical sites. Designed for radiologists, mammography centers, and health systems.
• cmTriage FDA-cleared AI tool for mammography workflow optimization. Prioritizes mammography cases, flagging suspicious findings for immediate radiologist review and reducing turnaround time for critical cases. Works across all breast densities with PACS integration. Designed for radiology practices and imaging centers.
• cmAssist AI-powered mammography decision support providing lesion localization, bounding, and classification of anomalies as suspicious or verifiable benign, with confidence scores. Commercially available in Brazil (ANVISA-cleared); in development in the US. Designed for radiologists performing breast cancer screening.

Quantifiable outcome

• 3× higher mortality rate in women with BAC (7.8% vs 2.3%)
• +4 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration5 records

AI capability6 records

Feature4 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Rezolut ImagingcoreTechnology or Integration · 23 January 2026Agreement to implement cmAngio software across Rezolut's imaging network, enabling detection of breast arterial calcifications on routine mammograms alongside breast cancer screening. Deployment began January 23rd, 2026.
• TherapixelcoreStrategic or Co-development Partner · 9 December 2025Partnership to integrate CureMetrix's cmAngio (FDA-cleared BAC detection) with Therapixel's MammoScreen (breast cancer detection AI) into a unified platform enabling radiologists to screen for both breast cancer and breast arterial calcifications through a single installation.
• American Heart Association Center for Health Technology & InnovationcoreStrategic or Co-development Partner · 3 November 2025CureMetrix joined the AHA Center for Health Technology & Innovation's Innovators' Network, contributing AI-driven solutions including FDA-cleared cmAngio software for BAC detection and collaborating on clinical outcome studies to develop digital health solutions and improve healthcare outcomes.
• Microsoft PIN (Precision Imaging Network)coreGTM or Marketing PartnerPart of Microsoft Health Solutions Radiology Workflow portfolio, the Precision Imaging Network connects AI developers with healthcare providers to deliver advanced imaging intelligence at scale.
• ExscientiaminorStrategic or Co-development PartnerCollaboration announced in June 2024 between Exscientia and CureMetrix for AI-driven drug R&D applications.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• Aidence: European radiology AI company focused on lung and other oncology imaging AI. Emerging player in clinical AI that competes for the same hospital AI deployment budgets and PACS integration points as CureMetrix.

Direct peers

• Volpara Health: Breast density and risk assessment software provider used by imaging centers worldwide. Direct competitor in automated breast density analysis (cmDensity's category) and mammography reporting workflow tools.
• Densitas: AI breast density and mammography quality analytics company. Direct peer competing specifically in automated breast density assessment (cmDensity) and mammography reporting workflows.
• Lunit: South Korean medical imaging AI company providing breast and chest X-ray AI solutions, deployed in 3,000+ hospitals globally. Direct peer in mammography AI and named integration partner via the Microsoft Precision Imaging Network.
• iCAD: Specialist in breast health AI and analytics, including ProFound AI for breast cancer detection and breast density assessment. Direct competitor in mammography AI decision support and density classification.
• Therapixel: French AI mammography company whose MammoScreen product detects breast cancer on screening mammograms. Direct peer to CureMetrix in mammography AI; CureMetrix and Therapixel announced a partnership in Dec 2025 to integrate cmAngio (BAC) with MammoScreen (cancer detection) into a unified platform.
• DeepHealth (RadNet subsidiary): AI radiology company acquired by RadNet that offers breast cancer detection and workflow AI integrated across a large imaging network. Direct peer in mammography AI with vertical integration advantages via RadNet's imaging centers.

Broad incumbents

• Hologic: Dominant mammography equipment manufacturer (3Dimensions, Genius AI) with bundled AI capabilities across breast imaging. Broad incumbent that competes via integrated hardware-software offerings in the same radiology customer base.
• GE HealthCare: Global medical imaging OEM with mammography systems (Pristina) and AI-enabled radiology workflow offerings. Broad incumbent competing through hardware-software bundling across the same imaging center customer base.
• Siemens Healthineers: Major imaging OEM with mammography systems (MAMMOMAT) and AI-augmented radiology portfolio. Broad incumbent overlapping with CureMetrix's hospital and imaging center customers.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/CureMetrix
• LinkedInlinkedin.com/company/curemetrix

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CureMetrix